Clinical Resources

ICD Primary Prevention Benefit Estimator

Assessing ICD Benefit in Non-Ischemic and Ischemic Cardiomyopathy

LVEF (%)

%

Etiology

Ischemic cardiomyopathy

Non-ischemic dilated

HCM

Arrhythmogenic (ARVC)

Other

NYHA Class

Class I

Class II

Class III

Class IV

QRS duration ≥120 msCRT-D candidate

Syncope of unknown origin

Sustained VT or VFChanges to secondary prevention

Life expectancy > 1 year

Currently on optimal medical therapy ≥3 months

LVEF reassessed after 3+ months of OMT

Results

ACC/AHA Guideline Class —

Estimated 5-Year Mortality Benefit —

Enter LVEF and clinical parameters.

Reference

Al-Khatib SM et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias. JACC. 2018;72(14):e91-e220.